The Procter & Gamble Company (NYSE: PG) is scheduled to report second quarter 2020 earnings results on Thursday, January 23, before the market opens. Analysts have projected earnings to improve to $1.37 per share from the year-ago number of $1.25 per share. Revenue is estimated to grow 5% year-over-year to $18.3 billion.
P&G is likely to see strong organic sales on the strength of its product portfolio along with favorable volumes and price/mix factors. Last quarter, organic sales grew 7%. The company’s innovation and marketing efforts are also expected to drive growth.
P&G’s strategic acquisitions and divestitures will help solidify the product lineup and prove beneficial to results. Earlier this month, the company announced plans to acquire the female body care company Billie Inc.
P&G is also likely to benefit from its cost reduction efforts as well as lower commodity costs which could drive margins. However, adverse currency impacts are likely to dampen the quarterly results.
In the first quarter of 2020, P&G beat consensus estimates for both revenue and earnings. Revenue increased 7% to $17.7 billion while core EPS was $1.37.
Last quarter, Procter & Gamble raised the outlook for fiscal 2020 all-in sales growth from 3-4% to 3-5% growth. The company also raised its guidance range on fiscal 2020 all-in GAAP EPS growth to 225-243%. The range for core EPS growth was raised to 5-10% from the prior range of 4-9%.
P&G’s shares have gained 37% in the past one year. The majority of analysts have rated the stock as Buy with the remaining giving it a rating of Hold. The stock has an average price target of $130.30.
Most Popular
United Parcel Service (UPS) seems on track to regain lost strength
Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company